Features associated with the development of hallucinations in Parkinson's disease
Article first published online: 21 APR 2006
Acta Neurologica Scandinavica
Volume 114, Issue 4, pages 239–243, October 2006
How to Cite
Benbir, G., Özekmekçi, S., Çinar, M., Beskardes, F., Apaydin, H. and Erginöz, E. (2006), Features associated with the development of hallucinations in Parkinson's disease. Acta Neurologica Scandinavica, 114: 239–243. doi: 10.1111/j.1600-0404.2006.00644.x
- Issue published online: 9 JUN 2006
- Article first published online: 21 APR 2006
- Accepted for publication February 24, 2006
- Parkinson's disease;
- REM behavior disorder;
- motor complication;
- dopaminergic therapy
Objective – To identify features related to the development of hallucinations in Parkinson's disease (PD).
Materials and methods – Seventy PD patients with hallucinations (group 1) and 60 PD patients without hallucinations (group 2) were evaluated for disease severity, presence of motor complications, rapid eye movement (REM) behavior disorder (RBD), and antiparkinsonian drug profile. The ages at the emergence of hallucinations and duration of disease in group 1 were matched with the ages at the last visit of those in group 2.
Results – Disease severity and presence of motor complications were similar in both groups. RBD was more frequently encountered among hallucinators than among non-hallucinators (P = 0.007). The mean duration and daily doses of levodopa and other dopaminergic drugs did not differ in both groups; however, the usage of anticholinergics and amantadine were significantly more frequent in group 2, unexpectedly.
Conclusions – The presence of RBD was significantly more common in hallucinators; however, severity of PD, duration and daily doses of dopaminergic drugs were not associated with the emergence of hallucinations.